RE:RE:RE:RE:Am I Out Of Line Here?"Back in the middle of our teens when Mark Day was CEO Bioasis had a plan to develope xB3-001. Yes it was dilutive,,not nearly to the point we see coming to us here,,,was that plan wrong??,,,,,"
You can run a company by the standard of excellence or you can do things half-azzed. BTI's history is of the half-azzed. As a preclinical company BTI should have always had 2 years of cash and never gone into debt. Going into debt and living a state of permanent financial emergency with no cash and no control of its own destiny and dependence on partners sworn to secrecy was a financial disaster waiting to happen. Mark Day's 8 non-human primate trials with Phase 0 for the best candidates while moving forward was another half-azzed strategy building on Hutchison's half-azzed Phase 0 strategy that he came late to. This company needs to move to a Phase I and get definitive data. We need a company with excellence in finance that boldlly moves to excellence in the clinic. Hopefully Biodexa has the cash, scale, and plan to put the half-azzed behind and manifest excellence.